In January 2006, the MGFT department at CING introduced in the Republic of Cyprus the carrier screening of the CYP21A2 gene for the diagnosis of 21-hydroxylase deficiency (21-OHD), the most common cause of CAH [21]. This evidence concerns the gene CYP21A2 and classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency.